Needham upgraded Doximity from Hold to Buy and set a new price target of $38.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $58.00 | Neutral | Goldman |
| 11/14/2024 | $33.00 → $53.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/13/2024 | $40.00 → $60.00 | Buy → Hold | Canaccord Genuity |
| 11/8/2024 | $19.00 → $41.00 | Underweight → Equal Weight | Wells Fargo |
| 11/8/2024 | $70.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 10/15/2024 | $35.00 → $52.00 | Equal Weight → Overweight | Barclays |
| 8/9/2024 | $38.00 | Hold → Buy | Needham |
| 7/18/2024 | $27.00 → $19.00 | Equal Weight → Underweight | Wells Fargo |
4 analysts have expressed a variety of opinions on Doximity (NYSE:DOCS) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 2 2 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 2 1 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $29.00, and a low estimate of $19.00. Observing a downward trend, the cur
Wells Fargo analyst Stan Berenshteyn downgrades Doximity (NYSE:DOCS) from Equal-Weight to Underweight and lowers the price target from $27 to $19.
10-Q - Doximity, Inc. (0001516513) (Filer)
8-K - Doximity, Inc. (0001516513) (Filer)
SCHEDULE 13G/A - Doximity, Inc. (0001516513) (Subject)
Total revenues of $136.8 million, up 20% year-over-year Net income growth of 44% and adjusted EBITDA growth of 41% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024. "Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers," said Jeff Tangney, co-founder and CEO of Doximity. "We're proud to help physicians save time, so they can provide better care for their patients." Fiscal 2025 Second Quarter Financial Highlights All comparisons, unless otherwise noted, are to the three months ended September 30, 2023. Revenue:
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that Nate Gross, co-founder and chief strategy officer, and Anna Bryson, chief financial officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 11:30 a.m. GMT/6:30 a.m. ET. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date w
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members includ
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
SC 13G - Doximity, Inc. (0001516513) (Subject)
SC 13G - Doximity, Inc. (0001516513) (Subject)
Total revenues of $136.8 million, up 20% year-over-year Net income growth of 44% and adjusted EBITDA growth of 41% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024. "Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers," said Jeff Tangney, co-founder and CEO of Doximity. "We're proud to help physicians save time, so they can provide better care for their patients." Fiscal 2025 Second Quarter Financial Highlights All comparisons, unless otherwise noted, are to the three months ended September 30, 2023. Revenue:
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members includ
Total revenues of $126.7 million, up 17% year-over-year Net income growth of 46% and adjusted EBITDA growth of 42% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 first quarter ended June 30, 2024. "We were pleased to deliver strong profits and record engagement last quarter, as we beat on both our top and bottom lines," said Jeff Tangney, co-founder and CEO of Doximity. "Last quarter, a record 590,000 unique providers used our AI, telehealth, messaging, and scheduling workflow tools to save time and better serve their patients." Fiscal 2025 First Quarter Financial Highlights All compa
With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati
Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one
Goldman initiated coverage of Doximity with a rating of Neutral and set a new price target of $58.00
Morgan Stanley upgraded Doximity from Underweight to Equal-Weight and set a new price target of $53.00 from $33.00 previously
Canaccord Genuity downgraded Doximity from Buy to Hold and set a new price target of $60.00 from $40.00 previously